FRANKFURT, Feb 7 (Reuters) - The European Union's drugs regulator said on Wednesday it will assess the impact on the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk. (Reporting by Ludwig Burger)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.34 USD | +0.61% | +0.97% | +25.40% |
02:16pm | FTC seeks more information on Novo Holdings-Catalent deal | RE |
May. 02 | Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
839.2 DKK | -3.89% | -5.74% | 556B | ||
755.9 USD | -2.68% | +4.28% | 681B | ||
56.34 USD | +0.61% | +0.97% | 10.2B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.40% | 10.2B | |
+29.68% | 681B | |
+20.34% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.32% | 235B | |
+4.36% | 199B | |
-11.49% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- EU watchdog to assess availability of drugs made at Catalent sites sold to Novo